CHICAGO--(EON: Enhanced Online News)--Advanced Cooling Therapy (ACT) has been awarded a group purchasing agreement as a Breakthrough Technology for Patient Temperature Management Products and Accessories with Premier Inc., effective January 1, 2017. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for ACT’s novel Esophageal Cooling Device (ECD).
“We are thrilled about the opportunity to work with Premier’s members to further the adoption and use of the ECD to manage the warming and cooling of patients in the clinical setting”
The ECD is designed to modulate and control patient temperature when clinically indicated through a single use, fully-enclosed triple lumen system that is inserted into the esophagus. Two lumens attach to existing temperature modulation equipment while a third lumen simultaneously allows gastric decompression and drainage. The ECD can be rapidly inserted by most trained healthcare professionals, in similar fashion to a standard gastric tube, and can be used to control patient temperature in the operating room, recovery room, emergency room, or ICU. No other products on the market are approved to use the esophageal environment for whole-body temperature modulation.
The ECD received FDA de novo clearance in June of 2015 for use with the Medi-Therm III by Stryker® and received FDA 510(k) clearance in January 2016 for use with the Blanketrol® II and III Hyper-Hypothermia systems made by Cincinnati Sub-Zero, a Gentherm Company. It received its CE Mark in Europe in 2014, with an expanded indication for use up to 120 hours in 2016, and is licensed for sale in Canada and Australia.
“We are thrilled about the opportunity to work with Premier’s members to further the adoption and use of the ECD to manage the warming and cooling of patients in the clinical setting,” commented Robin Drassler, VP of North American Sales for ACT. “The importance of temperature management is increasingly appreciated in a growing spectrum of conditions, and the ease of use of our device, without requiring additional capital purchases, has resulted in rapid adoption across North America. The ability to work with Premier’s members will help further accelerate this growth by facilitating the on-boarding of this breakthrough technology across a wider range of hospitals.”
Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,750 U.S. hospitals and 130,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.
Advanced Cooling Therapy’s technology platform provides a novel method to control patient temperature where clinically indicated using the esophageal environment.